| Identification | Back Directory | [Name]
N1,N4-Di-2-pyridinyl-1,4-benzenedimethanamine | [CAS]
55778-02-4 | [Synonyms]
WZ 811
CS-567
WZ 811, >=98%
WZ-811; WZ811
N,N'-Di-2-pyridinyl-1,4-benzenedimethanamine
N1,N4-Di-2-pyridinyl-1,4-benzenedimethanamine
1,4-Benzenedimethanamine, N1,N4-di-2-pyridinyl-
N,N'-(1,4-PHENYLENEBIS(METHYLENE))DIPYRIDIN-2-AMINE
N,N'-(1,4-phenylenebis(methylene))bis(pyridin-2-amine)
N1,N4-Di-2-pyridinyl-1,4-benzenedimethanamine USP/EP/BP
N-[[4-[(pyridin-2-ylamino)methyl]phenyl]methyl]pyridin-2-amine
N1,N4-di-2-pyridinyl-1,4-benzenedimethanamine WZ811
WZ 811 N,N'-Di-2-pyridinyl-1,4-benzenedimethanamine | [EINECS(EC#)]
200-256-5 | [Molecular Formula]
C18H18N4 | [MDL Number]
MFCD18086914 | [MOL File]
55778-02-4.mol | [Molecular Weight]
290.362 |
| Chemical Properties | Back Directory | [Melting point ]
192-194℃ (methanol ) | [Boiling point ]
493.2±35.0 °C(Predicted) | [density ]
1.229±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥7mg/mL | [form ]
powder | [pka]
6.55±0.10(Predicted) | [color ]
white to tan | [InChI]
1S/C18H18N4/c1-3-11-19-17(5-1)21-13-15-7-9-16(10-8-15)14-22-18-6-2-4-12-20-18/h1-12H,13-14H2,(H,19,21)(H,20,22) | [InChIKey]
KBVFRXIGQQRMEF-UHFFFAOYSA-N | [SMILES]
C(Nc1ccccn1)c2ccc(CNc3ccccn3)cc2 |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
22-36/37/38 | [Safety Statements ]
26 | [WGK Germany ]
3 | [HS Code ]
2933.39.6190 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral
Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| Hazard Information | Back Directory | [Description]
The CXC chemokine receptor-4 (CXCR4) is a G protein-coupled receptor that is specific for stromal cell-derived factor-1 (SDF-1/ CXCL12). Activation of CXCR4 promotes homing of hematopoietic stem cells, chemotaxis and quiescence of lymphocytes, and growth and metastasis of certain cancer cell types. Moreover, CXCR4 on CD4+ T-cells is used by CXCR4-selective HIV forms as a gateway for T-cell infection. WZ811 is a potent inhibitor of binding of an SDF-1 peptide mimic to CXCR4 (EC50 = 0.3 nM).1 It prevents SDF-1/CXCL12-mediated modulation of cAMP (EC50 = 1.2 nM) in cells and blocks SDF-1-induced Matrigel™ invasion by MDA-MB-231 human breast adenocarcinoma cells (EC50 = 5.2 nM).1 The effectiveness of WZ811 in animals remains to be elucidated. | [Uses]
N1,N4-di-2-Pyridinyl-1,4-benzenedimethanamine acts as an inhibitor for the chemokine receptor CXCR4. | [in vivo]
WZ811 (40 mg/kg, p.o.) blocks the lymphocytic leukemia cells growth on mouse xenograft models, and inhibits CXCR4/PI3K/AKT signaling pathway in mouse xenograft model of lymphocytic leukemia[2]. | [IC 50]
CXCR4: 0.3 nM (EC50) | [References]
[1] zhan w, liang z, zhu a, et al. discovery of small molecule cxcr4 antagonists. journal of medicinal chemistry, 2007, 50(23): 5655-5664.
[2] choi w t, duggineni s, xu y, et al. drug discovery research targeting the cxc chemokine receptor 4 (cxcr4). journal of medicinal chemistry, 2011, 55(3): 977-994. |
|
|